PLYX
Polaryx Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.00
+0.50%Aug 25, 2026, 12:30 UTC
Polaryx Therapeutics announced it is on track to initiate its SOTERIA Phase 2 basket trial for PLX-200 in the fourth quarter of 2026, following FDA authorization, CRO engagement, and Fast Track Designation across all four planned indications.
Source:May 28, 2026, 00:00 UTC
Polaryx Therapeutics, Inc. signed a $10 million PIPE private placement financing, issuing 2,502,696 shares of common stock at approximately $4.00 per share.